BioCentury
ARTICLE | Clinical News

TXB presents Novastan Phase III data

March 13, 2000 8:00 AM UTC

Texas Biotech (TXB) presented data from a Phase III study of 304 patients with heparin-induced thrombocytopenia (HIT) showing that Novastan argatroban, a synthetic thrombin inhibitor, gave a significant improvement compared to historical controls on the primary end point of all-cause death, all-cause amputation or new thrombosis over 37 days. Last month, TXB received an approvable letter from the FDA for Novastan to prevent or treat thrombosis in patients with HIT. Data were presented at the American College of Cardiology meeting in Anaheim. ...